Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
23 studies found for:    "Noonan syndrome 5"
Show Display Options
Download search resultsDownload the search results for:
"Noonan syndrome 5" (23 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
Condition: Hepatitis C
Interventions: Drug: daclatasvir;   Drug: asunaprevir;   Drug: Ribavirin
2 Completed Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)
Condition: Hepatitis C, Chronic
Interventions: Drug: IDX719;   Drug: Placebo
3 Completed An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
Condition: Hepatitis C Virus
Intervention:
4 Not yet recruiting Phase 3b, Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg;   Drug: Ribavirin 200Mg Tablet
5 Active, not recruiting A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Condition: Chronic Hepatitis C
Interventions: Drug: ravidasvir hydrochloride;   Drug: sofosbuvir;   Drug: ribavirin
6 Completed Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/VOX;   Drug: SOF/VEL
7 Not yet recruiting A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
Condition: HCV
Interventions: Drug: elbasvir/grazoprevir;   Drug: Sofosbuvir;   Drug: Ribavirin
8 Completed Ph IIA Study (SOC +/- NS5B)
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325;   Drug: Placebo;   Drug: Peg-interferon alfa-2a;   Drug: Ribavirin
9 Completed TD-6450 SAD and MAD in Healthy Subjects
Condition: Hepatitis C
Interventions: Drug: TD-6450;   Drug: Placebo
10 Completed TD-6450 MAD Study in HCV Infected Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: TD-6450;   Drug: Placebo
11 Completed A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Condition: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: Drug: PPI-461;   Drug: Placebo
12 Completed A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-383;   Drug: Placebo
13 Unknown  A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
Condition: Chronic Hepatitis C Infection
Interventions: Drug: JNJ-47910382 30 mg;   Drug: JNJ-47910382 90 mg;   Drug: JNJ-47910382 200 mg;   Drug: Placebo
14 Completed Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
15 Completed Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: PPI-668;   Drug: BI 207127 Dose 1;   Drug: BI 207127 Dose 2;   Drug: Faldaprevir;   Drug: Ribavirin;   Drug: BI 207127 Placebo
16 Terminated Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Condition: Chronic Hepatitis C Infection
Interventions: Drug: Placebo;   Drug: JNJ-47910382
17 Completed A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Condition: HCV Infection
Interventions: Drug: GS-5885;   Drug: Placebo
18 Completed A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
Condition: Hepatitis C, Chronic
Interventions: Drug: PPI-668;   Drug: Placebo
19 Completed Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo
20 Completed A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: GSK2878175;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.